PhilipCCompMD

Oncology • Oklahoma City, OK

Hematologic Oncology

Professor, Medicine, University of Oklahoma College of Medicine

Join to view full profile

Dr. Comp is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Comp's full profile

Already have an account?

Office
800 NE 10th St
Oklahoma City, OK 73104
Phone+1 405-271-8299

Fax+1 405-271-3064
Is this information wrong?

Education & Training

University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 1974 - 1976
University of Pennsylvania Health SystemResidency, Internal Medicine, 1971 - 1974
University of Washington School of MedicineClass of 1971

Certifications & Licensure

OK State Medical License 1974 - 2024
PA State Medical License 1972 - 1976
American Board of Allergy and Immunology Allergy & Immunology
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

Elected Member The American Society for Clinical Investigation, 1986
Whos Who in Medicine and Healthcare Marquis Whos Who

Clinical Trials

Protein S and Myocardial Infarction Start of enrollment: 1992 May 01
Completed

Publications & Presentations

PubMed

PFA-100 System: A New Method for Assessment of Platelet Dysfunction.
Mammen, E., Gosselin, R., Greenberg, C., Hoots, W., Kessler, C., Larkin, E., Liles, D., Nugent, D., Comp, P.> ;Seminars in Thrombosis and Hemostasis. 2023 Dec 13
Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis.
Tafur AJ, Dale G, Cherry M, Wren JD, Mansfield AS, Comp P, Rathbun S, Stoner JA> ;Thromb. Res.. 2015-12-01
Should coagulation tests be used to determine which oral contraceptive users have an increased risk of thrombophlebitis?
Philip C Comp> ;Contraception. 2006 Jan 1
Treatment and management of acute venous thromboembolic disease.
Philip C Comp> ;Thrombosis Research. 2003 Jan 1
Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.
Philip C Comp> ;Pharmacotherapy. 2003 Jun 1
PFA-100 system: a new method for assessment of platelet dysfunction.
Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ> ;Semin. Thromb. Hemost.. 1998-01-01
Preliminary data from a field trial of the PFA-100 system.
Mammen EF, Alshameeri RS, Comp PC> ;Semin. Thromb. Hemost.. 1995-01-01
Some clotting factors in plasma during danazol therapy: free and total protein S, but not C4b-binding protein, are elevated by danazol therapy.
Thorisdottir H, Evans JA, Schwartz HJ, Comp P, Haluschak J, Ratnoff OD> ;J. Lab. Clin. Med.. 1992-06-01
The natural anticoagulant protein S is decreased in male smokers.
Scott BD, Esmon CT, Comp PC> ;Am. Heart J.. 1991-07-01
Overview of the hypercoagulable states.
Comp PC> ;Semin. Thromb. Hemost.. 1990-04-01
Protein S deficiency occurs in the nephrotic syndrome.
Vigano-D'Angelo S, D'Angelo A, Kaufman CE, Sholer C, Esmon CT, Comp PC> ;Ann. Intern. Med.. 1987-07-01
Role of platelets in lysis of dilute plasma clots: requirement for metabolically active platelets.
Lockhart MS, Comp PC, Taylor FB> ;J. Lab. Clin. Med.. 1979-08-01
Coagulolysis assay in the detection of deep vein thrombosis in the orthopedic patient. A preliminary report.
Steves, C. R., Kopta, J. A., Taylor, F. B., Jacocks, R., Comp, P. C.> ;Clin Orthop Relat Res. 1979 Jul 01
A lysine-absorbable plasminogen activator is elevated in conditions associated with increased fibrinolytic activity.
Comp, P. C., Jacocks, R. M., Rubenstein, C., Radcliffe, R.> ;J Lab Clin Med. 1981 May
Protein C, isolation and potential use in prevention of thrombosis.
Esmon, C. T., Taylor, F. B., Hinshaw, L. B., Chang, A., Comp, P. C., Ferrell, G., Esmon, N. L.> ;Dev Biol Stand. 1987
Coagulation and thrombosis with OC use: physiology and clinical relevance.
Comp, P. C.> ;Dialogues Contracept. 1996
Phospholipid composition controls thromboplastin sensitivity to individual clotting factors.
Smith, S. A., Comp, P. C., Morrissey, J. H.> ;J Thromb Haemost. 2006 Apr
Laboratory evaluation of protein S status.
Comp, P. C.> ;Semin Thromb Hemost. 1990 Apr
Activation of protein C in vivo.
Comp, P. C., Jacocks, R. M., Ferrell, G. L., Esmon, C. T.> ;J Clin Invest. 1982 Jul
The activation and effects of protein C, an antithrombotic protein, in vivo.
Comp, P. C.> ;Surv Synth Pathol Res. 1984
Generation of fibrinolytic activity by infusion of activated protein C into dogs.
Comp, P. C., Esmon, C. T.> ;J Clin Invest. 1981 Nov
Familial protein S deficiency is associated with recurrent thrombosis.
Comp, P. C., Nixon, R. R., Cooper, M. R., Esmon, C. T.> ;J Clin Invest. 1984 Dec
Heparin-protein C interaction.
Comp, P. C.> ;Nouv Rev Fr Hematol. 1984
The dilute whole blood clot lysis assay: a screening method for identifying postoperative patients with a high incidence of deep venous thrombosis.
Comp, P. C., Jacocks, R. M., Taylor, F. B.> ;J Lab Clin Med. 1979 Jan
A 5.3-kb deletion including exon XIII of the protein S alpha gene occurs in two protein S-deficient families.
Schmidel, D. K., Nelson, R. M., Broxson, E. H., Comp, P. C., Marlar, R. A., Long, G. L.> ;Blood. 1991 Feb 1
Join now to see all

Grant Support

Improved Reagents To Monitor Oral AnticoagulationNational Center For Research Resources2004–2006
Protein S And Myocardial InfarctionNational Heart, Lung, And Blood Institute1992–1995
Protein S And Myocardial InfarctionNational Heart, Lung, And Blood Institute1991
Hereditary And Acquired Protein S DeficiencyNational Heart, Lung, And Blood Institute1986–1990
The Physiology Of Human Protein CNational Heart, Lung, And Blood Institute1985

Hospital Affiliations

OU HealthOklahoma City, Oklahoma
Oklahoma City VA Medical CenterOklahoma City, Oklahoma